TrialSignal
Clinical trial intelligence report
Treatment of Psoriatic Arthritis With hOKT3γ1 (Ala-Ala)
Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.
Generated
Jun 20, 2026
NCT ID
NCT00239720
Status
TERMINATED
Phase
Phase 2
Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Executive brief
Investment-Ready Snapshot
The clinical trial evaluated the safety and efficacy of hOKT3γ1 (Ala-Ala), a monoclonal antibody targeting CD3 on T cells, in patients with psoriatic arthritis unresponsive to standard therapies. The study was sponsored by the National Institute of Allergy and Infectious Diseases (NIAID) and aimed to provide a new treatment option for patients with severe disease.
Source & freshness
Provenance
https://clinicaltrials.gov/study/NCT00239720
Indication
Arthritis, Psoriatic
Modality
monoclonal antibody
Target
Psoriatic Arthritis
Intervention
hOKT3gamma1(Ala-Ala), Placebo
Source record
Protocol Description
Detailed source ingestion pending.
Source record
Outcome Measures
Detailed source ingestion pending.
Source record
Eligibility
Detailed source ingestion pending.
AI analysis
Known Results And Readout Context
Detailed source ingestion pending.
IP intelligence
Patent And IP Landscape
Detailed source ingestion pending.
Source record
Contacts
Detailed source ingestion pending.